

REMARKS

Claims 13-21 are pending in this application. Claims 13-19 are allowed. Claims 20 and 21 are rejected. Claim 20 is amended herein. Support for the amendments can be found, for example, in cancelled Claim 1 as originally filed. The Applicants respectfully request reconsideration of the claims in view of this amendment and response. There is no issue of new matter. None of the claims are objected to.

CLAIM REJECTIONS UNDER 35 USC §112, SECOND PARAGRAPH

Claims 20 and 21 are rejected under 35 U.S.C. § 112, second paragraph, as the Examiner alleges that the recitation of “effective pharmaceutical composition” is indefinite. In addition, the Examiner suggests that while being enabling for a method of making an immunogenic pharmaceutical composition, the specification does not reasonably provide enablement for the broadly claimed generic pharmaceutical composition.

As suggested by the Examiner, the Applicants have amended Claim 20 to make reference to the immunogenic function of the composition by inserting “immunogenic” between “effective” and “pharmaceutical” in line 1 of Claim 20. As rejected Claim 21 depends from Claim 20, this added limitation in Claim 20 is now incorporated in Claim 21. The Applicants respectfully submit their amendment to Claims 20 and 21 obviates this rejection.

Therefore, in view of the foregoing remarks and amendments, the Applicants respectfully request reconsideration and withdrawal of this section 112, second paragraph rejection to the extent that it applies to Claims 20 and 21, as amended.

The Applicants reserve the right to prosecute, in one or more patent applications, the cancelled claims, the claims as originally filed, and any other claim that is supported by the instant specification. In view of the foregoing amendments and remarks, Applicants respectfully submit that the subject application is in condition for allowance. The Applicants thank the Examiner for the Office Action and believe this response to be a full and complete response to such Office Action. Accordingly, favorable reconsideration and allowance of the pending and new claims is earnestly solicited. If it would expedite prosecution of this application, the Examiner is invited to confer with the Applicants' undersigned agent.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Jason C. Fedon". The signature is fluid and cursive, with the first name "Jason" and last name "Fedon" clearly distinguishable.

Jason C. Fedon

Agent for Applicants

Registration No. 48,138

GlaxoSmithKline Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-6150
Facsimile (610) 270-5090
B45082D1\roal.doc